Jun 2026 (Q2 FY26) — Jul 30, 2026
Illumina Q2 FY26 — Strong Clinical Demand Drives Raised Full-Year Guidance
Read the full callIllumina (ILMN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Illumina earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,159 | +9.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 21.1 | +0.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 207 | −11.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
39 of 41 judged targets kept · 32 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Non-GAAP diluted EPS | $1.20 to $1.25 | Mar 2026 | Altogether, non-GAAP EPS of $1.31 per diluted share grew approximately 10% year-over-year | Achieved |
| Non-GAAP diluted EPS | $5.05 to $5.20 | Dec 2025 | this equates to diluted EPS guidance of $5.30 to $5.40, an increase of $0.12 at the midpoint versus our prior guide | Revised Up |
| Clinical sequencing consumables revenue growth | double-digit to mid-teens | Dec 2025 | We are raising our growth outlook in clinical markets towards the high end of our prior guide and now expect mid-teens growth for the year. | On Track |
2 of ILLUMINA, INC.'s 73 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 70 more targets are in the full ledger.
Claimed
- Revenue grew 9.5% year-over-year to $1.16 billion, with Rest of World organic revenue up 8.1%.
- NovaSeq X placements remained high with more than 95 units placed in the quarter.
- Clinical sequencing consumables revenue grew 15% ex China, with U.S./Canada growing above 20%.
- Non-GAAP EPS of $1.31 grew 10% year-over-year, exceeding guidance.
- Full-year 2026 guidance for Rest of World organic revenue growth was raised to greater than 5% and diluted EPS to $5.30-$5.40.
Qualified
- Research and academic markets remain cautious, with mid- to high single-digit declines expected for 2026.
- Slower growth in Europe, Middle East, and Latin America for sequencing consumables due to ongoing near-term dynamics.
- Higher freight and memory costs were absorbed in the quarter, impacting gross margin.
Price
$262.66 +0.05% · +$0.12
Performance +175.2% 1Y
1Y: $95.46 on 17 Oct 2025 → $262.66. High $293.69 (5 Oct 2026), low $95.03 (29 Oct 2025).
- Previous close
- $262.54
- 52-week range
- $95.03 – $293.69
- One year
- +163.98%
Overview
- Symbol
- ILMN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
39 of 41 judged targets kept · 32 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Non-GAAP diluted EPS | $1.20 to $1.25 | Mar 2026 | Altogether, non-GAAP EPS of $1.31 per diluted share grew approximately 10% year-over-year | Achieved |
| Non-GAAP diluted EPS | $5.05 to $5.20 | Dec 2025 | this equates to diluted EPS guidance of $5.30 to $5.40, an increase of $0.12 at the midpoint versus our prior guide | Revised Up |
| Clinical sequencing consumables revenue growth | double-digit to mid-teens | Dec 2025 | We are raising our growth outlook in clinical markets towards the high end of our prior guide and now expect mid-teens growth for the year. | On Track |
Claimed
- Revenue grew 9.5% year-over-year to $1.16 billion, with Rest of World organic revenue up 8.1%.
- NovaSeq X placements remained high with more than 95 units placed in the quarter.
- Clinical sequencing consumables revenue grew 15% ex China, with U.S./Canada growing above 20%.
- Non-GAAP EPS of $1.31 grew 10% year-over-year, exceeding guidance.
- Full-year 2026 guidance for Rest of World organic revenue growth was raised to greater than 5% and diluted EPS to $5.30-$5.40.
Qualified
- Research and academic markets remain cautious, with mid- to high single-digit declines expected for 2026.
- Slower growth in Europe, Middle East, and Latin America for sequencing consumables due to ongoing near-term dynamics.
- Higher freight and memory costs were absorbed in the quarter, impacting gross margin.
The full ledger
Open ILLUMINA, INC.’s full ledger
A free account opens 5 company ledgers a month. All 73 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — Apr 30, 2026
Illumina Q1 FY26 — Strong Clinical Growth and NovaSeq X Demand Drive Raised Outlook
Read the full callDec 2025 (Q4 FY25) — Feb 5, 2026
Illumina Q4 FY25 — Clinical Consumables Drive Strong Performance
Read the full callEvery analysed call
Illumina earnings calls (ILMN)
Financials
What the filings say
Net profit, year on year: −12% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,080 | 1,104 | 1,041 | 1,059 | 1,084 | 1,159 | 1,091 | 1,159 |
| Operating profit | 741 | 174 | 164 | 214 | 227 | 202 | 209 | 245 |
| Operating margin | 68.6% | 15.8% | 15.8% | 20.2% | 20.9% | 17.4% | 19.2% | 21.1% |
| Other income | -21 | 12 | 18 | 92 | -7 | 176 | -52 | 15 |
| Interest | 36 | 26 | 25 | 25 | 25 | 26 | 24 | 24 |
| Profit before tax | 720 | 186 | 182 | 306 | 220 | 378 | 157 | 260 |
| Tax rate | 2.1% | 0.0% | 28.0% | 23.2% | 31.8% | 11.6% | 14.7% | 20.4% |
| Net profit | 705 | 186 | 131 | 235 | 150 | 334 | 134 | 207 |
| EPS ($ per share) | 4.43 | — | 0.83 | 1.49 | 0.98 | — | 0.88 | 1.37 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 3,083 | 4,067 | 4,723 | 5,485 | 1,142 | -19 | -1,242 | -392 |
| Total liabilities | 3,114 | 2,703 | 2,891 | 4,477 | 5,653 | 4,366 | 3,930 | 3,921 |
| Fixed assets | 1,075 | 889 | 922 | 1,024 | 1,091 | 1,007 | 815 | 759 |
| Investments | 2,368 | 1,372 | 1,662 | 107 | 26 | 6 | 93 | 215 |
| Total assets | 6,959 | 7,316 | 7,585 | 15,217 | 12,252 | 10,111 | 6,303 | 6,644 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,142 | 1,051 | 1,080 | 545 | 392 | 478 | 837 | 1,079 |
| Cash from investing | -1,813 | 745 | -554 | -1,069 | -591 | -231 | -178 | -55 |
| Cash from financing | 594 | -897 | -766 | -51 | 1,000 | -1,210 | -570 | -744 |
| Net cash flow | -81 | 898 | -232 | -578 | 779 | -963 | 79 | 291 |
| Capital expenditure | -296 | -209 | -189 | -208 | -286 | -195 | -128 | -148 |
| Free cash flow | 846 | 842 | 891 | 337 | 106 | 283 | 709 | 931 |
ILMN revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2027 | Q2 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Core Illumina | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | +9.4% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
ILMN operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | Sep 2025 Q3 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|
| NovaSeq X placements | 91We placed 91 instruments during the quarter, bringing the installed base to 630.Source: earnings call transcript | 60+Our NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1, following more than 90 placements in Q4.Source: earnings call transcript | 55+In Q3, we had another strong quarter for the NovaSeq X with more than 55 instruments placed in line with our goal of 50 to 60 placements per quarter.Source: earnings call transcript | 95+Rest of World organic revenue grew 8.1%, above the high end of our guidance and demand for NovaSeq X remained high more than 3 years after launch with more than 95 placements in the quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2027 · share of revenue
- United States and Canada 56%
- EMEA 32%
- Asia Pacific 7%
- CN 5% ↓ 2 pt
As ILMN cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
180 filings between Nov 3, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$84.6K
2 purchases by 1 insider
Sales
$592.86M
112 sales by 5 insiders
17% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 27
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
- 23
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 other filings, 4 option exercises, 1 disposition to issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Meister Keith A. | — | $591.13M | Sep 4, 2026 |
| Davies Scott M | — | $531.3K | Jul 30, 2026 |
| Leckman Patricia | — | $529.7K | Jun 5, 2026 |
| Wedel Christensen Jakob | — | $366.1K | Aug 18, 2026 |
| Ericksen Scott D | — | $305.1K | May 29, 2026 |
| Gottlieb Scott | $84.6K | — | Feb 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Thaysen Jacob Chief Executive Officer | Tax withheld | 1,303 | $382.7K |
| Sep 30, 2026 | Meister Keith A. Director | Award | 107 | $23.5K |
| Sep 30, 2026 | Ullem Scott B. Director | Award | 113 | $24.8K |
| Sep 8, 2026 | Coletti Julie Ann Chief Legal Officer | Award | 4,549 | $0 |
| Sep 8, 2026 | Coletti Julie Ann Chief Legal Officer | Award | 14,214 | $0 |
| Sep 5, 2026 | Barnard Steven SVP, Chief Technology Officer | Tax withheld | 408 | $86.1K |
| Sep 4, 2026 | Meister Keith A. Director | Sale | 100,650 | $21.98M |
| Sep 4, 2026 | Meister Keith A. Director | Sale | 11,351 | $2.49M |
| Sep 4, 2026 | Meister Keith A. Director | Sale | 7,500 | $1.63M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 13,717 | $3.01M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 13,261 | $2.87M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 9,721 | $2.12M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 6,656 | $1.47M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 8,439 | $1.82M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 14,196 | $3.08M |
| Sep 3, 2026 | Meister Keith A. Director | Sale | 9,961 | $2.21M |
| Sep 2, 2026 | Meister Keith A. Director | Sale | 10,620 | $2.27M |
| Sep 2, 2026 | Meister Keith A. Director | Sale | 57,488 | $12.26M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 16,990 | $3.90M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 28,439 | $6.56M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 4,873 | $1.10M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 54,309 | $12.36M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 24,363 | $5.57M |
| Aug 27, 2026 | Meister Keith A. Director | Sale | 9,405 | $2.17M |
| Aug 26, 2026 | Meister Keith A. Director | Sale | 38,213 | $8.59M |
| Aug 26, 2026 | Meister Keith A. Director | Sale | 425 | $96.6K |
| Aug 26, 2026 | Meister Keith A. Director | Sale | 53,123 | $11.99M |
| Aug 26, 2026 | Meister Keith A. Director | Sale | 14,782 | $3.35M |
| Aug 25, 2026 | Meister Keith A. Director | Sale | 42 | $9.5K |
| Aug 25, 2026 | Meister Keith A. Director | Sale | 38,201 | $8.64M |
| Aug 25, 2026 | Meister Keith A. Director | Sale | 92,776 | $20.90M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 3,883 | $854.8K |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 133,256 | $29.25M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 86,825 | $18.98M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 8,187 | $1.78M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 12,602 | $2.73M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 9,365 | $2.02M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 13,668 | $2.93M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 6,821 | $1.46M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 13,050 | $2.78M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 7,151 | $1.51M |
| Aug 21, 2026 | Meister Keith A. Director | Sale | 4,528 | $952.9K |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 21,147 | $4.60M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 15,263 | $3.31M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 9,078 | $1.90M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 18,405 | $3.97M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 42,218 | $9.06M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 3,563 | $743.1K |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 71,939 | $15.35M |
| Aug 20, 2026 | Meister Keith A. Director | Sale | 29,805 | $6.34M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ILLUMINA, INC.
Free account. Everything above stays public.
Write why you follow ILLUMINA, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading